Annual Drug Patent Expirations for ILEVRO
Ilevro is a drug marketed by Harrow Eye and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for ILEVRO.
This drug has seventy-seven patent family members in twenty-six countries.
The generic ingredient in ILEVRO is nepafenac. Two suppliers are listed for this compound. Additional details are available on the nepafenac profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
